Filter news by date Month AllJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year20182017201620152014 Apply Subscribe to latest news Email address* Sign up Galderma receives Positive Opinion through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel for Acne Patient Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biotherapy for Skin Diseases FDA Approves Galderma’s prescription-strength Differin Gel for over-the-counter use in treatment of acne in the U.S. Galderma’s Epiduo Gel approved for the treatment of acne in Japan Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease Nestlé Skin Health SHIELD Receives Corporate Leadership Award from the American Skin Association Nestlé Skin Health to Form Non-Prescription Acne Joint Venture with Guthy-Renker ATP and Nestlé Skin Health’s Daylong Announce Exclusive Global Sun Care Partnership Nestlé Skin Health Appoints Dr. Johannes J. Baensch as Chief Scientific Officer Nestlé Skin Health Invests $46 Million in Factory Extension in Canada Nestlé Skin Health Promotes a Life Course of Healthy Skin and Provides New Educational Tools During Active Aging Week 2015 Nestlé Skin Health builds CHF 54 million factory in Brazil Pagination Previous page Previous Next page Next
Galderma receives Positive Opinion through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel for Acne Patient
Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biotherapy for Skin Diseases
FDA Approves Galderma’s prescription-strength Differin Gel for over-the-counter use in treatment of acne in the U.S.
Nestlé Skin Health Promotes a Life Course of Healthy Skin and Provides New Educational Tools During Active Aging Week 2015
